You are here: Industry Insights > Lilly

News List

Lilly’s Emgality nabs third-to-market migraine nod but aims to be 'treatment of choice' in CGRP fiercepharma
September 29, 2018
Lilly will provide 12 months of Emgality to patients for free under an access program, an executive said. (Eli Lilly)
Lilly’s snaps up Chugai’s experimental diabetes drug pharmatimes
September 29, 2018
Lilly has entered into an agreement to develop Chugai’s OWL833, a oral non-peptidic GLP-1 receptor agonist currently in Phase I for type II diabetes.
Lilly links with Anima pharmatimes
July 25, 2018
Eli Lilly is teaming up with Anima Biotech in an exclusive collaboration to discover and develop translation inhibitors for several protein targets.
Anima Biotech Announces Collaboration with Lilly americanpharmaceuticalreview
July 24, 2018
Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima's Translation Control Therapeutics platform.
Lilly diabetes drug Trulicity leapfrogs to No. 2 ad spender for June fiercepharma
July 19, 2018
With six months down in 2018 and six to go, Humira is on track to keep its pharma TV spending crown for 2018.
Athenex Names Timothy Cook as Senior Vice President of Global Commercial Oncology firstwordpharma
July 10, 2018
thenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Timothy Cook as Senior V
FDA greenlights Lilly's Olumiant in rheumatoid arthritis, with major caveats pharmafile
June 07, 2018
Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely active rheumatoid arthritis (RA) in adult patients who have had an inadequate response to one or more tumour n
Eli Lilly’s President of Oncology to retire pharmafile
June 07, 2018
Just as it ramps up its cancer-fighting efforts, Eli Lilly has revealed that its Senior Vice President and President of Lilly Oncology Sue Mahony is set to retire from her role, effective 31 August.
Lilly's cancer business loses its chief just as it's leaning on oncology for growth biospectrumasia
May 29, 2018
Eli Lilly is leaning on oncology as a key pillar for growth going forward, but with news that its president of the business, Sue Mahony, Ph.D., is retiring, the drugmaker will need to find new leadership for the unit.
Eli Lilly to buy AurKa Pharma financialexpress
May 21, 2018
Eli Lilly and Company has signed an agreement to acquire AurKa Pharma, established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page